

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in this application.

The following amendments do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed. Amendments to the claims were made for purposes of more clearly stating the claimed subject matter and do not add new matter or alter the scope of the claims.

**Listing of Claims:**

1. (Currently amended) A denatured laminin selective peptide antagonist comprising the sequence S-T-Q wherein said laminin selective peptide antagonist binds with substantially greater affinity to denatured laminin than to native laminin.
2. (Previously presented) The antagonist of claim 1 wherein the antagonist is a peptide comprising an amino acid sequence NH<sub>2</sub>-S-T-Q-N-A-S-L-L-S-L-T-V-C-COOH (SEQ ID NO 1).
3. (Previously presented) The antagonist of claim 1 wherein the antagonist is a peptide comprising an amino acid sequence NH<sub>2</sub>-K-G-G-C-S-T-Q-N-A-Q-L-L-S-L-I- V-G-K-A-COOH (SEQ ID NO 2).
4. (Previously presented) The antagonist of claim 1 wherein the antagonist is a peptide comprising an amino acid sequence NH<sub>2</sub>-K-G-G-S-T-Q-N-A-Q-L-L-S-L-I-V- G-K-A-COOH (SEQ ID NO 3).
5. (Original) The antagonist of claim 1 wherein the binding affinity of the denatured laminin selective antagonist to denatured laminin is substantially greater than the binding affinity of said antagonist to native laminin.
6. (Original) The antagonist of claim 1 wherein the binding affinity of the denatured laminin selective antagonist to denatured laminin is 100-fold greater than the binding affinity of said antagonist to native laminin.
7. (Original) The antagonist of claim 1 wherein the denatured laminin selective antagonist inhibits cellular interaction with denatured laminin.
8. (Original) A pharmaceutical composition comprising a denatured laminin selective antagonist and a pharmaceutically acceptable excipient.

9. (Original) The pharmaceutical composition of claim 8 wherein the composition comprises a cytotoxic agent.

10. (Original) The pharmaceutical composition of claim 8 wherein the composition comprises a radioactive material.

11. (Original) The pharmaceutical composition of claim 8 wherein the composition comprises a cytostatic agent.

12-36 (Canceled)

37. (New) A denatured laminin selective peptide antagonist comprising the sequence L-S-L-T-V wherein said laminin selective peptide antagonist binds with substantially greater affinity to denatured laminin than to native laminin.

38. (New) A denatured laminin selective peptide antagonist comprising the sequence L-S-L-I-V wherein said laminin selective peptide antagonist binds with substantially greater affinity to denatured laminin than to native laminin.

39. (New) A denatured laminin selective peptide antagonist comprising at least one conservative substitution of the sequence L-S-L-T-V wherein said laminin selective peptide antagonist binds with substantially greater affinity to denatured laminin than to native laminin.